hologic inc. - HOLX

HOLX

Close Chg Chg %
75.09 -1.44 -1.92%

Closed Market

73.65

-1.44 (1.92%)

Volume: 2.55M

Last Updated:

Dec 13, 2024, 4:00 PM EDT

Company Overview: hologic inc. - HOLX

HOLX Key Data

Open

$74.76

Day Range

73.50 - 75.30

52 Week Range

70.24 - 84.67

Market Cap

$17.04B

Shares Outstanding

226.94M

Public Float

223.70M

Beta

0.96

Rev. Per Employee

N/A

P/E Ratio

22.59

EPS

$3.35

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.99M

 

HOLX Performance

1 Week
 
-2.24%
 
1 Month
 
-6.30%
 
3 Months
 
-9.24%
 
1 Year
 
3.76%
 
5 Years
 
38.57%
 

HOLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About hologic inc. - HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

HOLX At a Glance

Hologic, Inc.
250 Campus Drive
Marlborough, Massachusetts 01752
Phone 1-508-263-2900 Revenue 4.03B
Industry Medical Specialties Net Income 789.50M
Sector Health Technology Employees 7,063
Fiscal Year-end 09 / 2025
View SEC Filings

HOLX Valuation

P/E Current 22.594
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.318
Price to Sales Ratio 4.764
Price to Book Ratio 3.651
Price to Cash Flow Ratio 14.939
Enterprise Value to EBITDA 15.262
Enterprise Value to Sales 4.844
Total Debt to Enterprise Value 0.136

HOLX Efficiency

Revenue/Employee 570,621.549
Income Per Employee 111,779.697
Receivables Turnover 6.713
Total Asset Turnover 0.441

HOLX Liquidity

Current Ratio 3.686
Quick Ratio 3.031
Cash Ratio 2.25

HOLX Profitability

Gross Margin 55.524
Operating Margin 24.073
Pretax Margin 21.465
Net Margin 19.589
Return on Assets 8.631
Return on Equity 15.561
Return on Total Capital 10.137
Return on Invested Capital 10.298

HOLX Capital Structure

Total Debt to Total Equity 51.813
Total Debt to Total Capital 34.129
Total Debt to Total Assets 29.03
Long-Term Debt to Equity 50.55
Long-Term Debt to Total Capital 33.297
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Hologic Inc. - HOLX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.63B 4.86B 4.03B 4.03B
Sales Growth
+49.14% -13.66% -17.12% -0.00%
Cost of Goods Sold (COGS) incl D&A
1.88B 1.89B 1.81B 1.79B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
406.90M 430.10M 323.40M 309.00M
Depreciation
88.00M 89.20M 89.60M 99.30M
Amortization of Intangibles
318.90M 340.90M 233.80M 209.70M
COGS Growth
+20.21% +0.77% -4.53% -0.83%
Gross Income
3.75B 2.97B 2.22B 2.24B
Gross Income Growth
+69.57% -20.89% -25.14% +0.67%
Gross Profit Margin
+66.64% +61.07% +55.15% +55.52%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.27B 1.32B 1.28B 1.27B
Research & Development
276.30M 283.40M 294.30M 272.80M
Other SG&A
994.40M 1.04B 987.60M 994.80M
SGA Growth
+19.20% +3.99% -2.99% -1.12%
Other Operating Expense
- - - -
-
Unusual Expense
29.50M (11.50M) 233.90M 107.70M
EBIT after Unusual Expense
2.45B 1.66B 707.10M 862.50M
Non Operating Income/Expense
1.30M 23.60M 80.10M 124.70M
Non-Operating Interest Income
1.40M 12.90M 120.50M 108.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
93.60M 95.10M 111.10M 122.10M
Interest Expense Growth
-21.21% +1.60% +16.82% +9.90%
Gross Interest Expense
93.60M 95.10M 111.10M 122.10M
Interest Capitalized
- - - -
-
Pretax Income
2.36B 1.59B 676.10M 865.10M
Pretax Income Growth
+135.66% -32.73% -57.43% +27.95%
Pretax Margin
+41.92% +32.66% +16.78% +21.46%
Income Tax
491.40M 286.20M 220.10M 75.60M
Income Tax - Current - Domestic
538.30M 353.40M 296.50M 105.80M
Income Tax - Current - Foreign
23.20M 99.00M 32.70M 41.90M
Income Tax - Deferred - Domestic
(57.50M) (139.30M) (81.50M) (58.40M)
Income Tax - Deferred - Foreign
(12.60M) (26.90M) (27.60M) (13.70M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.87B 1.30B 456.00M 789.50M
Minority Interest Expense
- - - (1.80M)
-
Net Income
1.87B 1.30B 456.00M 789.50M
Net Income Growth
+67.82% -30.43% -64.98% +73.14%
Net Margin Growth
+33.23% +26.77% +11.31% +19.59%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.87B 1.30B 456.00M 789.50M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.87B 1.30B 456.00M 789.50M
EPS (Basic)
7.2808 5.1764 1.8479 3.3493
EPS (Basic) Growth
+71.53% -28.90% -64.30% +81.25%
Basic Shares Outstanding
257.05M 251.53M 246.77M 235.72M
EPS (Diluted)
7.2062 5.1291 1.8326 3.3235
EPS (Diluted) Growth
+70.99% -28.82% -64.27% +81.35%
Diluted Shares Outstanding
259.71M 253.84M 248.83M 237.55M
EBITDA
2.89B 2.08B 1.26B 1.28B
EBITDA Growth
+89.31% -28.08% -39.16% +1.17%
EBITDA Margin
+51.31% +42.74% +31.37% +31.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 87.688
Number of Ratings 23 Current Quarters Estimate 1.009
FY Report Date 12 / 2024 Current Year's Estimate 4.276
Last Quarter’s Earnings 1.01 Median PE on CY Estimate N/A
Year Ago Earnings 4.08 Next Fiscal Year Estimate 4.699
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 20 20
Mean Estimate 1.01 1.05 4.28 4.70
High Estimates 1.02 1.11 4.44 4.89
Low Estimate 0.97 0.98 4.10 4.54
Coefficient of Variance 1.24 2.83 1.41 1.69

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 9 10
OVERWEIGHT 2 2 1
HOLD 12 9 9
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Hologic Inc. - HOLX

Date Name Shares Transaction Value
Nov 8, 2024 Stephen P. MacMillan Chairman, President and CEO; Director 1,276,122 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Jan Verstreken Group President, International 103,675 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Karleen Marie Oberton Chief Financial Officer 107,752 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 John M. Griffin General Counsel 187,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Erik S. Anderson Div. Pres., Breast & Skeletal 20,639 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 8, 2024 Essex D. Mitchell Chief Operating Officer 25,036 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 9, 2024 Brandon Schnittker Div. President, GYN Surgical 3,735 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.11 per share 310,415.85
Jul 25, 2024 Stephen P. MacMillan Chairman, President and CEO; Director 1,157,562 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $80.13 per share 92,755,443.06
Jul 25, 2024 Stephen P. MacMillan Chairman, President and CEO; Director 44,039 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 12, 2024 Amy A. McBride-Wendell Director 4,536 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Christiana Stamoulis Director 45,472 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Christiana Stamoulis Director 4,536 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Sally W. Crawford Director 132,927 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Sally W. Crawford Director 141,966 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.74 per share 3,796,170.84
Mar 12, 2024 Sally W. Crawford Director 132,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.4 per share 10,155,622.80
Mar 12, 2024 Sally W. Crawford Director 4,536 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Amy A. McBride-Wendell Director 20,730 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Charles J. Dockendorff Director 1,572 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.21 per share 119,802.12
Mar 12, 2024 Scott T. Garrett Director 48,611 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2024 Scott T. Garrett Director 4,536 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Hologic Inc. in the News